TopiVert Seeks Slot In Dry Eye Disease

 
• By Kevin Grogan

The London-based group has begun a Phase IIb/III study evaluating TOP1630 which has a safety and tolerability profile that could prove superior to current treatments such as Allergan's market leader Restasis.

EyeDrops
There are over 300 million dry eye disease sufferers globally • Source: Shutterstock

UK biotech TopiVert Ltd. is progressing well in its bid to challenge Allergan PLC and Shire PLC for a slice of the dry-eye disease market and has moved a promising candidate into late-stage trials.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas